Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences Inc. (DTIL) filed a Current Report on Form 8-K on May 14, 2025. The filing serves as a Regulation FD disclosure regarding an update to the Company's PBGENE-DMD program.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused on a specific corporate event rather than periodic financial results.
Material Changes
The material change disclosed is the issuance of a press release providing an update on the PBGENE-DMD program. No financial or operational changes compared to prior periods are detailed in this specific filing.
Guidance, Outlook, and Management Commentary
Management announced a live webcast scheduled for May 15, 2025, at 8:00 a.m. Eastern Time to discuss the program update. The press release is incorporated by reference as Exhibit 99.1. The filing explicitly states that the information furnished in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Key Facts for Investor Verification
- Verify the specific clinical or operational details of the PBGENE-DMD program update in the attached press release (Exhibit 99.1).
- Confirm the date and time of the investor webcast: May 15, 2025, at 8:00 a.m. ET.
- Note that this 8-K does not contain audited or unaudited financial data; refer to the most recent 10-K or 10-Q for financial metrics.
- Review the legal disclaimer regarding the "furnished" status of the press release information.